Clinical Trial Update: Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial comparing eribulin followed by FAC versus paclitaxel followed by FEC in early-stage HER2-negative breast cancer; trial completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)
• FAC (FAC (fluorouracil, doxorubicin, cyclophosphamide))
• FEC
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-09-22